Products
Silevimig Biosimilar Biparatopic Antibody (Rabies Virus Glycoprotein G) for Research
Cat No.: GMP-Bios-INN-1386
Anti-Rabies Lyssavirus Glycoprotein G epitope III therapeutic antibody (Pre-made Silevimig biosimilar,Bispecific ((G1_L-kappa)_scFv-G1(h-CH2-CH3))) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Silevimig (development code GR1801) is a bispecific antibody targeting rabies lyssavirus (rabies virus. It is developed by Genrix (Shanghai) Biopharmaceuticals for Rabies in preregistration development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1386-1mg | 1mg | |
| GMP-Bios-INN-1386-10mg | 10mg | |
| GMP-Bios-INN-1386-100mg | 100mg | |
| GMP-Bios-INN-1386-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Silevimig biosimilar, Bispecific ((G1_L-kappa)_scFv-G1(h-CH2-CH3)): Anti-Rabies Lyssavirus Glycoprotein G epitope III;Rabies Lyssavirus Glycoprotein G epitope I therapeutic antibody |
| INN Name | Silevimig |
| Target | Rabies Lyssavirus Glycoprotein G epitope III;Rabies Lyssavirus Glycoprotein G epitope I |
| Format | Bispecific ((G1_L-kappa)_scFv-G1(h-CH2-CH3)) |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1;G1 |
| VD LC | Kappa;Lambda |
| Highest_Clin_Trial (Jan '20) | Preregistration |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2023 |
| Year Recommended | 2024 |
| Companies | Genrix (Shanghai) Biopharmaceuticals |
| Conditions Approved | na |
| Conditions Active | Rabies |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
